IceCure Medical Statistics
Total Valuation
IceCure Medical has a market cap or net worth of $7.88 million. The enterprise value is -$4.06 million.
| Market Cap | 7.88M |
| Enterprise Value | -4.06M |
Important Dates
The last earnings date was Wednesday, August 12, 2026, before market open.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
IceCure Medical has 3.43 million shares outstanding. The number of shares has increased by 35.73% in one year.
| Current Share Class | 3.43M |
| Shares Outstanding | 3.43M |
| Shares Change (YoY) | +35.73% |
| Shares Change (QoQ) | +25.86% |
| Owned by Insiders (%) | 35.78% |
| Owned by Institutions (%) | 3.87% |
| Float | 2.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.00 |
| Forward PS | 1.41 |
| PB Ratio | 0.66 |
| P/TBV Ratio | 0.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.87, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.87 |
| Quick Ratio | 2.15 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -106.52 |
Financial Efficiency
Return on equity (ROE) is -228.31% and return on invested capital (ROIC) is -121.20%.
| Return on Equity (ROE) | -228.31% |
| Return on Assets (ROA) | -73.88% |
| Return on Invested Capital (ROIC) | -121.20% |
| Return on Capital Employed (ROCE) | -140.33% |
| Weighted Average Cost of Capital (WACC) | 8.30% |
| Revenue Per Employee | $57,203 |
| Profits Per Employee | -$244,638 |
| Employee Count | 69 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 1.03 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.22% in the last 52 weeks. The beta is 0.47, so IceCure Medical's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -92.22% |
| 50-Day Moving Average | 3.70 |
| 200-Day Moving Average | 12.06 |
| Relative Strength Index (RSI) | 33.00 |
| Average Volume (20 Days) | 164,337 |
Short Selling Information
The latest short interest is 40,780, so 1.19% of the outstanding shares have been sold short.
| Short Interest | 40,780 |
| Short Previous Month | 37,525 |
| Short % of Shares Out | 1.19% |
| Short % of Float | 1.85% |
| Short Ratio (days to cover) | 0.50 |
Income Statement
In the last 12 months, IceCure Medical had revenue of $3.95 million and -$16.88 million in losses. Loss per share was -$6.66.
| Revenue | 3.95M |
| Gross Profit | 1.43M |
| Operating Income | -16.72M |
| Pretax Income | -16.88M |
| Net Income | -16.88M |
| EBITDA | -16.44M |
| EBIT | -16.72M |
| Loss Per Share | -$6.66 |
Balance Sheet
The company has $12.03 million in cash and $90,000 in debt, with a net cash position of $11.94 million or $3.49 per share.
| Cash & Cash Equivalents | 12.03M |
| Total Debt | 90,000 |
| Net Cash | 11.94M |
| Net Cash Per Share | $3.49 |
| Equity (Book Value) | 11.90M |
| Book Value Per Share | 3.47 |
| Working Capital | 10.86M |
Cash Flow
In the last 12 months, operating cash flow was -$15.87 million and capital expenditures -$69,000, giving a free cash flow of -$15.94 million.
| Operating Cash Flow | -15.87M |
| Capital Expenditures | -69,000 |
| Depreciation & Amortization | 284,000 |
| Net Borrowing | -2.00M |
| Free Cash Flow | -15.94M |
| FCF Per Share | -$4.65 |
Margins
| Gross Margin | 36.10% |
| Operating Margin | -423.69% |
| Pretax Margin | -427.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IceCure Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -35.73% |
| Shareholder Yield | -35.73% |
| Earnings Yield | -214.17% |
| FCF Yield | -202.26% |
Analyst Forecast
The average price target for IceCure Medical is $22.67, which is 885.65% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $22.67 |
| Price Target Difference | 885.65% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 87.32% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 4, 2026. It was a reverse split with a ratio of 1:30.
| Last Split Date | Jun 4, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
IceCure Medical has an Altman Z-Score of -7.71 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.71 |
| Piotroski F-Score | 4 |